☆ 4.4 Review

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

CLINICAL PHARMACOKINETICS (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal et al.

Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma

Takeshi Aoyama et al.

Summary: This study investigated the relationship between plasma trough concentrations and safety of pazopanib in Japanese patients with renal cell carcinoma (RCC) or soft tissue sarcoma (STS). The study found that there was no significant difference in pazopanib trough concentrations between Japanese RCC and STS patients. The plasma trough concentrations showed significant and positive correlations with aspartate aminotransferase and alanine aminotransferase values.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Hematology

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts et al.

Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of Olutasidenib in patients with acute myeloid leukemia or myelodysplastic syndrome with mutant IDH1. The results showed that Olutasidenib, as monotherapy or in combination with azacitidine, was well tolerated and exhibited meaningful clinical activity. These findings provide a rationale for further evaluation of Olutasidenib in different populations of patients with myeloid malignancies.

LANCET HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

Stefanie L. Groenland et al.

Summary: The study examined the relationship between drug exposure and efficacy and toxicity in melanoma patients treated with dabrafenib plus trametinib. Results showed that trametinib exposure was related to survival, with a threshold of 15.6ng/mL. Patients with trametinib concentrations at or above this threshold had a significantly longer median overall survival compared to those with concentrations below the threshold. Exposure to dabrafenib and trametinib was not associated with clinically relevant toxicities.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

Add to Collection

Article Medical Laboratory Technology

Volumetric Absorptive Microsampling for the Therapeutic Drug Monitoring of Everolimus in Patients Who Have Undergone Liver Transplant

Seungji Yoo et al.

Summary: This study aimed to assess the applicability of VAMS for TDM of everolimus. The results showed good agreement between VAMS and venous blood sampling for the measurement of whole blood everolimus concentrations, suggesting that VAMS can substitute for more invasive venous blood sampling in the TDM of everolimus.

THERAPEUTIC DRUG MONITORING (2023)

Add to Collection

Article Chemistry, Multidisciplinary

Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer

Ma Ida Mohmaed Ali et al.

Summary: This study aimed to investigate whether the pharmacokinetic exposure of olaparib is associated with its efficacy and safety. The results showed that the exposure of olaparib is not related to PFS, suggesting that the approved dose can achieve sufficient target inhibition in the majority of patients.

PHARMACEUTICAL RESEARCH (2023)

Add to Collection

Article Oncology

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

Marinda Meertens et al.

Summary: The ADAPT ALEC trial aims to improve treatment outcomes for patients with advanced ALK+ NSCLC by using TDM-guided dosing of alectinib instead of fixed dosing.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma

Anne-Gaelle Dosne et al.

Summary: This study aimed to explore the relationship between serum phosphate concentrations and efficacy and safety outcomes in urothelial carcinoma patients treated with erdafitinib. Results showed that patients with higher serum phosphate levels had better overall survival, progression-free survival, and objective response rate. Additionally, an increase in phosphate concentration was associated with a significant increase in the incidence of specific adverse events.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors

Francois Mercier et al.

Summary: Entrectinib is an anti-cancer agent that inhibits TRKA/B/C, ROS1, and ALK. This study analyzed the exposure-response relationships of Entrectinib in patients with NTRK-, ROS1-, or ALK-positive tumors, and found that at a dose of 600 mg/day, Entrectinib provides an acceptable benefit-risk ratio in adults.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC

Neeraj Gupta et al.

Summary: The ALTA-1L trial compared brigatinib and crizotinib in ALK+ NSCLC patients, using a population PK model to estimate brigatinib exposures and analyze their effects on efficacy and safety. Brigatinib exposure was not significantly related to objective response rate, but higher exposure was associated with higher intracranial objective response rate.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Add to Collection

Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer

Anne-Gaelle Dosne et al.

Summary: The population PK-PD model evaluated the impact of erdafitinib concentrations on serum phosphate levels in cancer patients. Erdafitinib increased serum phosphate levels, which were used as a biomarker for its efficacy and safety. Dose adjustments based on phosphate levels and tolerability after 14 days of treatment were supported by the model simulations.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies

Helena Edlund et al.

Summary: The study aimed to examine the relationship between the exposure of Acalabrutinib and its active metabolite ACP-5862 with efficacy and safety responses in patients with B-cell malignancies. It was found that the fixed dose of Acalabrutinib at 100 mg twice daily was effective and safe for the treatment of patients with B-cell malignancies, with no clinically meaningful correlations observed between PK exposure and outcomes.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer

Stefanie D. Krens et al.

Summary: In this study, the relationship between cabozantinib exposure and response was explored in mRCC patients. The results showed that the average exposure to cabozantinib was low and there was no clear relationship with improved PFS.

BMC CANCER (2022)

Add to Collection

Article Oncology

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study

Wenyuan Xiong et al.

Summary: This study evaluated the dose-exposure relationship of Tepotinib and its metabolite, MSC2571109A, and found dose proportionality with once-daily dosing. Intrinsic and extrinsic factors had no clinically meaningful effects on Tepotinib PK. These findings provide valuable information for the appropriate use of Tepotinib.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer

Khushboo A. Gandhi et al.

Summary: This study evaluated the feasibility of therapeutic drug monitoring (TDM) of sunitinib in patients with metastatic renal cell carcinoma (mRCC). The study found that the optimal total trough plasma level (TTL) range of sunitinib for safety and efficacy was 60.75-82.3 ng/mL.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment

Zuzanna Synowiec et al.

Summary: The aim of this study was to investigate the relationship between axitinib steady-state trough concentration and treatment efficacy and toxicity. The results showed significant differences between measured axitinib trough concentration and treatment response, progression-free survival, and toxicity. These findings can be used to determine indications for axitinib therapy monitoring based on trough concentration measurements.

CLINICAL GENITOURINARY CANCER (2022)

Add to Collection

Article Pharmacology & Pharmacy

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study

Neeraj Gupta et al.

Summary: This study evaluated the efficacy and safety of mobocertinib in patients with EGFR mutations in lung cancer, and the results showed that the 160mg dose of mobocertinib had a favorable benefit-risk profile.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Oncology

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

S. L. Groenland et al.

Summary: Pharmacokinetically guided dose optimization of oral targeted therapies is feasible in clinical practice and significantly reduces the proportion of underexposed patients.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

Wenyuan Xiong et al.

Summary: This study analyzed the exposure-efficacy and exposure-safety relationships of tepotinib in the treatment of NSCLC, and concluded that the dosage of 500 mg/day tepotinib is appropriate for the treatment of NSCLC with METex14 skipping alterations.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients

Hirotsugu Kenmotsu et al.

Summary: The study evaluated the relationship between treatment efficacy and exposure of total and unbound erlotinib in NSCLC patients with EGFR-activating mutations, finding that there was no correlation between efficacy and exposure levels, indicating that the standard dose of 150 mg/day is sufficient for treating NSCLC harboring these mutations.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Pasi A. Jaenne et al.

Summary: Adagrasib demonstrated clinical efficacy without new safety signals in previously treated KRAS(G12C)-mutated NSCLC patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, Research & Experimental

Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer

Niels A. D. Guchelaar et al.

Summary: Therapeutic drug monitoring (TDM) for sorafenib is not of added value in daily clinical practice due to the limitations posed by toxicity that restrict dose escalations.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Advances in covalent drug discovery

Lydia Boike et al.

Summary: Covalent drugs have been widely used for over a century, but recent advances in tools for rational design have led to the successful development of potent and selective inhibitors, such as KRAS(G12C) inhibitors. The use of electrophile-first approaches and the emergence of chemoproteomics platforms have greatly enhanced the discovery and development of covalent drugs.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Rene J. Boosman et al.

Summary: This study investigates the exposure-response relationship of osimertinib in a real-life setting and finds no relationship between osimertinib exposure and efficacy, but an association between exposure and toxicity. Furthermore, it discovers the influence of EGFR mutation types on the efficacy of osimertinib.

PHARMACEUTICAL RESEARCH (2022)

Add to Collection

Article Oncology

Improving the tolerability of osimertinib by identifying its toxic limit

Bram C. Agema et al.

Summary: This study aimed to investigate the relationship between osimertinib exposure and severe toxicity and determine a safe toxic limit for a preventive dose reduction. The results showed a significant correlation between osimertinib clearance and severe toxicity. A preventive dose reduction in patients with high osimertinib exposure could reduce the risk of severe toxicity without compromising effectiveness.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma

Tingting Chen et al.

Summary: This study evaluated and compared the cost-effectiveness of PK-guided individualized treatment of sunitinib with its standard dose in patients with metastatic renal cell carcinoma (mRCC). The results showed that PK-guided treatment had higher QALY and lower costs, making it the dominant strategy.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour

Kim Westerdijk et al.

Summary: This study aimed to investigate the relationship between sunitinib exposure and treatment outcome in a real-world patient cohort. Patients with sunitinib-induced toxicity requiring dose reduction had significantly higher sunitinib exposure compared to those without toxicity, although the threshold for toxicity was lower than in clinical trials.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients

Stefanie L. Groenland et al.

Summary: In NSCLC patients treated with crizotinib and alectinib, higher minimum plasma concentrations were associated with prolonged progression-free survival, suggesting the importance of therapeutic drug monitoring for these agents.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Chemistry, Medicinal

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study

Maud Velev et al.

Summary: This study found a significant association between olaparib plasma exposure and the onset of serious adverse events in ovarian cancer patients, with a threshold of 2500 ng/mL trough concentration potentially useful for dose adjustment guidance.

PHARMACEUTICALS (2021)

Add to Collection

Article Oncology

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma

Masahide Fukudo et al.

Summary: Axitinib is an effective treatment for metastatic RCC, with significant variability in pharmacokinetics. Peak drug concentration at steady state can predict treatment response, while dose adjustment guided by pharmacokinetics may enhance efficacy and safety. Further investigation in a larger patient population is warranted.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies

Ana Ruiz-Garcia et al.

Summary: The study explored the relationship between Glasdegib exposure and adverse events, finding a significant correlation with dysgeusia, muscle spasms, renal toxicity, and QT interval prolonged. The survival benefit was not exposure-dependent, and the probability of developing AEs for safety endpoints was low, hence no starting dose adjustments for Glasdegib are recommended based on the observed safety profile.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies

Xuemin Jiang et al.

Summary: This study systematically analyzed the pharmacokinetics, efficacy, and safety of Ivosidenib, and found that the 500 mg once daily dose is effective for treating AML patients, but precautions should be taken for potential side effects.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

Add to Collection

Review Oncology

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

William A. Clarke et al.

Summary: Therapeutic drug monitoring (TDM) is not widely accepted in oncology but plays an important role in other medical fields. Imatinib and other oral chemotherapy drugs use a flat dosing approach, with numerous studies examining the correlation between blood concentrations and clinical effects. The International Association identified the need to develop consensus guidelines based on available data.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R Mato et al.

LANCET (2021)

Add to Collection

Article Chemistry, Medicinal

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data

Felicien Le Louedec et al.

Summary: The study found that a limited sampling strategy using the T0-1-2-4 design can accurately estimate ibrutinib exposure, with good accuracy even when removing the 1-hour or 2-hour sampling points. The correlation between actual AUC(IBRU) and C-min, C-ss was poor, and joint analysis of dihydrodiol-ibrutinib metabolite concentrations did not improve predictive performance. At least three samples within the pre-dose and 4-hour post-dose period are necessary for accurate estimation of ibrutinib exposure.

PHARMACEUTICALS (2021)

Add to Collection

Article Oncology

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Yi-Chieh Chen et al.

Summary: In lung cancer patients with EGFR mutations, daily treatment with 30mg of afatinib as initial therapy showed similar response rates, progression free survival, and overall survival compared to 40mg dose, but significantly fewer serious adverse drug reactions.

BMC CANCER (2021)

Add to Collection

Article Pharmacology & Pharmacy

Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer

Joseph Chen et al.

Summary: In the study on lorlatinib in patients with ALK-positive advanced NSCLC, exposure-response relationships were mainly observed in relation to the risk of hypercholesterolemia and treatment-emergent adverse events, while no statistically significant factors were identified regarding efficacy endpoints.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Oncology

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

Gottfried E. Konecny et al.

Summary: This study aimed to evaluate the correlations between rucaparib exposure and efficacy and safety endpoints in patients with recurrent ovarian carcinoma. Results showed that rucaparib exposure was positively correlated with efficacy and negatively correlated with safety.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes

Masahide Fukudo et al.

Summary: The study evaluated the pharmacokinetics of regorafenib and its correlation with clinical outcomes, suggesting that dose titration in Cycle 1 may improve efficacy and safety, warranting further investigation in a larger patient population.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol

Anna M. Mc Laughlin et al.

Summary: There is a correlation between blood drug concentrations and efficacy/toxicity for up to 80% of oral anticancer drugs. Therapeutic Drug Monitoring (TDM) can be used for dose optimization based on measured drug concentrations to improve outcomes. The ON-TARGET study aims to explore the feasibility of TDM in patients receiving certain anticancer drugs for renal-cell carcinoma treatment, with a focus on reducing severe toxicities.

CANCERS (2021)

Add to Collection

Article Oncology

Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study

L. Cerbone et al.

Summary: Cabozantinib has a demonstrated relationship between pharmacokinetics and pharmacodynamics, with severe toxicities associated with higher drug exposure and inefficacy associated with lower drug exposure. Plasma drug monitoring of cabozantinib may be useful in optimizing clinical practice.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020

M. Maliepaard et al.

Summary: The majority of registered anticancer agents have not established a dose-response relationship, and the selected posology is often poorly tolerable with high discontinuation and dose reduction rates. Due to the absence of dose-response data, it is often unknown if the optimal dose has been selected for anticancer agents.

ESMO OPEN (2021)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor

Ophelia Yin et al.

Summary: This analysis was conducted to evaluate the exposure-response relationships for efficacy and safety of Pexidartinib in tenosynovial giant cell tumor patients. The study found that higher Pexidartinib concentration correlated with better efficacy outcomes and smaller tumor sizes, but also increased the risk of ALT and AST-related adverse events. The results support the approved dosing regimen of 400mg twice daily without an initial loading dose by the US FDA.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Assessment of futibatinib exposure-response (E-R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA)

A. Hollebecque et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Hematology

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Jorge Cortes et al.

Summary: The study focused on the treatment of CP-CML patients with different doses of ponatinib, finding that the optimal benefit/risk outcomes were achieved with a starting dose of 45 mg and decreased to 15 mg upon response.

BLOOD (2021)

Add to Collection

Article Hematology

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

Philippe Rousselot et al.

Summary: Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for CML patients. This study evaluated therapeutic drug monitoring (TDM) to reduce dasatinib-associated pleural effusion (PlEff) incidence. Results showed that TDM during dasatinib treatment initiation significantly reduced the occurrence of PlEff in the long run without affecting molecular responses.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic-pharmacodynamic real-life study

Lauriane Goldwirt et al.

Summary: In this study, exposure-efficacy and tolerance analysis highlighted the interest of therapeutic drug monitoring to optimize therapeutic management in BRAFV600(mut) metastatic melanoma patients based on trough concentrations of dabrafenib and trametinib.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Precision Dosing of Targeted Therapies Is Ready for Prime Time

Stefanie L. Groenland et al.

Summary: In the era of precision medicine, personalized dosing based on pharmacokinetic exposure is rational and supported by evidence. The debate on whether randomized studies are needed to confirm the clinical value of precision dosing in oncology continues. Personalized dosing, extrapolating from selected patient populations to each individual with suboptimal exposure, could potentially lead to better treatment outcomes without the need for confirmatory trials.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Meeting Abstract Oncology

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N plus C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

Amishi Yogesh Shah et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

Leylah M. Drusbosky et al.

Summary: The MET exon 14 skipping mutation is present in a small percentage of lung cancer patients, but targeted inhibitors like capmatinib and tepotinib show promising clinical activity with tolerable toxicity profiles. Ongoing research aims to overcome acquired resistance and enhance the effectiveness of these agents.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Therapeutic drug monitoring of oral targeted antineoplastic drugs

Anna Mueller-Schoell et al.

Summary: Oral targeted antineoplastic drug (OAD) therapy is important for cancer patients, but high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. Therapeutic drug monitoring (TDM) can help individualize drug dosing and ensure treatment success.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose

Kim Westerdijk et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Oncology

Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma

Ganessan Kichenadasse et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

Add to Collection

Article Oncology

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

Takeshi Suzuki et al.

CLINICAL COLORECTAL CANCER (2020)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies

Fanny Gallais et al.

CLINICAL PHARMACOKINETICS (2020)

Add to Collection

Article Oncology

Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC).

Bradley J. Monk et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials

Mohamed Elmeliegy et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and GermlineBRCA1/2Mutations in the EMBRACA Trial

Yanke Yu et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Oncology

Clinical implications of food–drug interactions with small-molecule kinase inhibitors

G D Marijn Veerman et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer A Multicenter Phase 2 Trial

Shingo Miyamoto et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study

Satoshi Noda et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

Add to Collection

Article Oncology

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

Swan Lin et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

Add to Collection

Article Oncology

Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical

Nikki S. IJzerman et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma

Yuji Miura et al.

CLINICAL GENITOURINARY CANCER (2019)

Add to Collection

Article Oncology

Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer

Mitsuji Nagahama et al.

MEDICAL ONCOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study

Sander Zuidema et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Article Oncology

Application of time-dependent modeling for the exposure-efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients

Yvonne Y. Lau et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)

Add to Collection

Article Oncology

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Rastislav Bahleda et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Meeting Abstract Oncology

Alectinib exposure-response (ER) in ALK-inhibitor naive ALK-positive NSCLC patients: Pooled analysis across phase III studies.

Kevin Smart et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

Stefanie L. Groenland et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Meeting Abstract Hematology

Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies

Ying Ou et al.

BLOOD (2019)

Add to Collection

Article Pharmacology & Pharmacy

Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma

Linh Nguyen et al.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2019)

Add to Collection

Article Oncology

Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma

Satoshi Noda et al.

CLINICAL GENITOURINARY CANCER (2019)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients

Diansong Zhou et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Multidisciplinary Sciences

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer

Keiko Nakao et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Review Oncology

Clinically relevant drug interactions with multikinase inhibitors: a review

Koen G. A. M. Hussaarts et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)

Add to Collection

Article Biochemical Research Methods

Volumetric absorptive microsampling as an alternative tool for therapeutic drug monitoring of first-generation anti-epileptic drugs

Sofie Velghe et al.

ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2018)

Add to Collection

Article Oncology

Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

Steven Lacy et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

Add to Collection

Article Oncology

Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer

Peter N. Morcos et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

Add to Collection

Article Oncology

Abstract P5-21-21: Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer (ABC)

J Zheng et al.

CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma

Cora N. Sternberg et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Review Pharmacology & Pharmacy

Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?

Anouk E. Muller et al.

DRUGS (2018)

Add to Collection

Article Oncology

Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma

Shinya Takasaki et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer

Seiichi Hayato et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

Add to Collection

Article Oncology

Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?

Chor-Kuan Lim et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane

Annelieke E. C. A. B. Willemsen et al.

TARGETED ONCOLOGY (2018)

Add to Collection

Article Oncology

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Akiko Mita et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients

Sheima Farag et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

Huixin Yu et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Sven Wind et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Article Biochemical Research Methods

A Perspective on the Kinetics of Covalent and Irreversible Inhibition

John M. Strelow

SLAS DISCOVERY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma

Alexander Solms et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)

Add to Collection

Article Pharmacology & Pharmacy

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

Toshiyuki Tamai et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship

Marine Deppenweiler et al.

PHARMACOLOGICAL RESEARCH (2017)

Add to Collection

Article Oncology

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

R. B. Verheijen et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)

Add to Collection

Article Medical Laboratory Technology

Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma

Marine Rousset et al.

CLINICA CHIMICA ACTA (2017)

Add to Collection

Review Pharmacology & Pharmacy

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

Nienke A. G. Lankheet et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer

Kathryn Brown et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)

Add to Collection

Letter Oncology

Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al.

L. Goldwirt et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia

Yoji Ishida et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)

Add to Collection

Article Oncology

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma

N. Kramkimel et al.

TARGETED ONCOLOGY (2016)

Add to Collection

Article Oncology

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

J. C. -H. Yang et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Oncology

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development

Benjamin L. Lampson et al.

CANCER (2016)

Add to Collection

Article Oncology

Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

Daniele Ouellet et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

Add to Collection

Article Oncology

Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer

D. de Wit et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

Add to Collection

Article Oncology

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Remy B. Verheijen et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Article Oncology

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting

Stephane Bouchet et al.

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors

Jocelyn Zhou et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2016)

Add to Collection

Article Oncology

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

David J. Dorer et al.

LEUKEMIA RESEARCH (2016)

Add to Collection

Article Oncology

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Oncology

Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance

E. Funck-Brentano et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Review Pharmacology & Pharmacy

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia

Masatomo Miura

BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)

Add to Collection

Article Oncology

Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma

Satoshi Noda et al.

CLINICAL GENITOURINARY CANCER (2015)

Add to Collection

Article Oncology

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer

Hiroyuki Kobayashi et al.

CLINICAL LUNG CANCER (2015)

Add to Collection

Meeting Abstract Oncology

Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients.

Norihiko Tsuchiya et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma

Miki Shimada et al.

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2015)

Add to Collection

Article Multidisciplinary Sciences

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations

Shuang Xin et al.

SCIENTIFIC REPORTS (2015)

Add to Collection

Article Oncology

Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib

Yi Ling Teo et al.

TARGETED ONCOLOGY (2015)

Add to Collection

Meeting Abstract Hematology

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Philippe Rousselot et al.

BLOOD (2015)

Add to Collection

Article Medical Laboratory Technology

Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib

Djoeke de Wit et al.

THERAPEUTIC DRUG MONITORING (2014)

Add to Collection

Article Oncology

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

N. A. G. Lankheet et al.

BRITISH JOURNAL OF CANCER (2014)

Add to Collection

Article Oncology

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

A. B. Suttle et al.

BRITISH JOURNAL OF CANCER (2014)

Add to Collection

Article Oncology

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial

V. Gotta et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)

Add to Collection

Article Oncology

Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma

A. Thiery-Vuillemin et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma

Masahide Fukudo et al.

CLINICAL PHARMACOKINETICS (2014)

Add to Collection

Review Pharmacology & Pharmacy

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Huixin Yu et al.

CLINICAL PHARMACOKINETICS (2014)

Add to Collection

Article Oncology

Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

Alain Ravaud et al.

EUROPEAN JOURNAL OF CANCER (2014)

Add to Collection

Article Oncology

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Marcello Tiseo et al.

LUNG CANCER (2014)

Add to Collection

Review Oncology

Determining the optimal dose in the development of anticancer agents

Ron H. J. Mathijssen et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2014)

Add to Collection

Article Medical Laboratory Technology

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

Nienke A. G. Lankheet et al.

THERAPEUTIC DRUG MONITORING (2014)

Add to Collection

Article Oncology

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

Poe-Hirr Hsyu et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)

Add to Collection

Article Pharmacology & Pharmacy

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

Francis J. Giles et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)

Add to Collection

Article Pharmacology & Pharmacy

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Brian I. Rini et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2013)

Add to Collection

Meeting Abstract Hematology

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Feng Jin et al.

BLOOD (2013)

Add to Collection

Article Pharmacology & Pharmacy

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase

Richard A. Larson et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)

Add to Collection

Article Hematology

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

Francois Guilhot et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

Add to Collection

Article Oncology

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Robyn M. Emanuel et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

Naoto Takahashi et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)

Add to Collection

Article Oncology

Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis

Pascaline Boudou-Rouquette et al.

ONCOLOGIST (2012)

Add to Collection

Article Multidisciplinary Sciences

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study

Pascaline Boudou-Rouquette et al.

PLOS ONE (2012)

Add to Collection

Review Oncology

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Karel Eechoute et al.

CLINICAL CANCER RESEARCH (2011)

Add to Collection

Meeting Abstract Oncology

Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma

Y. Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib

Yuan-Yuan Zhao et al.

MEDICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

Brett E. Houk et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)

Add to Collection

Article Pharmacology & Pharmacy

Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia

N. Takahashi et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)

Add to Collection

Article Pharmacology & Pharmacy

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Ron J. Keizer et al.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)

Add to Collection

Article Oncology

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

George D. Demetri et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Chemistry, Analytical

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

B. Blanchet et al.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2009)

Add to Collection

Article Hematology

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson et al.

BLOOD (2008)

Add to Collection

Article Oncology

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

N. Widmer et al.

BRITISH JOURNAL OF CANCER (2008)

Add to Collection

Article Oncology

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

Michael Brave et al.

CLINICAL CANCER RESEARCH (2008)

Add to Collection

Meeting Abstract Oncology

Pharmacokinetics (PK) and pharmacodynamics (PD) of midostaurin (PKC412) in patients with acute myeloid leukemia (AML)

O. Yin et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Meeting Abstract Oncology

Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)

X. Wang et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Hematology

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stephane Picard et al.

BLOOD (2007)

Add to Collection

Article Oncology

Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors

Catherine Delbaldo et al.

CLINICAL CANCER RESEARCH (2006)

Add to Collection

Article Pharmacology & Pharmacy

Clinical pharmacokinetics of erlotinib in patients with solid tumors and. exposure-safety relationship in patients with non-small cell lung cancer

Jian-Feng Lu et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)

Add to Collection

Article Oncology

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

S Faivre et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.